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Abstract 
Amiodarone decreases plasma and tissue triiodothyronine (T,) and increases plasma cholesterol levels resembling changes een during hypothyroid- 
ism. To elucidate the mechanism of amiodarone-induced hypercholesterolemia we investigated gene expression of three key proteins in cholesterol 
metabolism (cholesterol 7a-hydroxylase, LDL receptor, HMG-CoA reductase) in livers of rats. Animals were treated with amiodarone or pro- 
pylthiouracil (to induce mild hypothyroidism). The LDL receptor mRNA was downregulated (~50%) in both amiodarone-treated and hypothyroid 
animals, while the other mRNA remained unchanged after 1Cday treatment. The results suggest hat amiodarone-induced hypercholesterolemia is 
associated with decreased LDL receptor mRNA levels. 
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1. Introduction 
A number of tissue effects in patients or experimental 
animals upon amiodarone medication are strikingly sim- 
ilar to those observed in hypothyroidism. For example, 
the lengthening of the cardiac action potential induced 
by amiodarone medication is similar to that observed in 
hypothyroidism [I]. Furthermore, hypothyroidism and 
amiodarone treatment are both associated with hyper- 
cholesterolemia. In patients, long-term amiodarone 
treatment induces a dose-dependent increase in plasma 
cholesterol [2]. The same increase was observed in rats 
[3]. Therefore it has been hypothesised that one of the 
mechanisms of action of amiodarone is the induction of 
a local ‘hypothyroid-like’ condition. Indeed, amiodarone 
treatment decreases plasma and tissue triiodothyronine 
(TJ concentrations [4]. This is due to a reduction of the 
5’-deiodination of thyroxine (TJ into T3 which is second- 
ary to an inhibition of T4 transport across the plasma 
membrane into the cell, resulting in increased plasma T4 
values. To elucidate the mechanism of amiodarone-in- 
duced hypercholesterolemia we investigated the gene ex- 
pression of three key proteins in the metabolism of 
cholesterol: the LDL receptor (responsible for the uptake 
of cholesterol into the liver), HMG-CoA reductase (the 
rate-limiting enzyme in the cholesterol biosynthesis), and 
cholesterol 7a-hydroxylase (catalyses the rate-limiting 
step in the synthesis of bile acids from cholesterol). All 
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these proteins are under thyroid hormone control. We 
studied the mRNA’s in livers of amiodarone treated rats 
and pair-fed controls, because amiodarone has a slight 
anorectic effect, and mildly hypothyroid animals. 
2. Materials and methods 
2.1. Materials 
Amiodarone was obtained from Sanofi B.V., Maassluis, The Nether- 
lands. Propylthiouracil was obtained from Sigma Chemical Company, 
St Louis, MO, USA. Cesium chloride was from JT. Baker BV, De- 
venter, The Netherlands. Formaldehyde, formamide, B-mercaptoetha- 
no1 and guanidine isothiocyanate were from Merck, Darmstadt, Ger- 
many. The cDNA probes for human LDL receptor (pLDLR3) [5] and 
HMG-CoA reductase @HRED-102) [6] were generous gifts from Dr 
D.W. Russell (Dallas, TX, USA). The cDNA for rat cholesterol 7a- 
hydroxylase (p7a-11) was kindly provided by Dr M. Noshiro [7] (Hiro- 
shima, Japan). A cDNA probe for rat Y-deiodinase was a gift from Dr 
R. Larsen [8] (Boston, MA, USA). The C/EBP cDNA was kindly 
provided by Dr S.L. McKnight [9] (Baltimore, MD, USA). 
2.2. Animals 
Male wistar rats (weight 270-325 g) were housed under normal con- 
ditions with free access to standard lab chow (except when stated 
otherwise) and tap water. In experiment I, a time-course xperiment, 
the rats (two per time point) received a daily aqueous suspension of 
amiodarone (10 mg/lOO g SW) by gastric tube for 2,4, 8 and 14 days. 
Controls received daily water by gastric tube for 14 days. Prior to 
amiodarone treatment 2 ml blood was taken from each rat by cardiac 
puncture to determine baseline plasma T3 and cholesterol concentra- 
tions. In experiment II rats were divided into three groups of six rats. 
Group A was fed ad libitum on standard lab chow, receiving 10 mg/lOO 
g BW amiodarone daily by gastric tube for two weeks. Group B were 
pair-fed controls of group A. Group C was fed ad libitum on standard 
lab chow, receiving propylthiouracil 4 mg/lOO g BW daily by gastric 
tube for two weeks. Twenty-four hours after the last administration 
blood (EDTA) was collected by cardiac puncture and plasma stored at 
-20°C. The liver was removed and stored in liquid nitrogen. All animal 
experiments were approved by our ethics committee. 
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2.3. Assays 
Plasma cholesterol and triglyceride concentrations were determined 
using a fully enzymatic, kinetic UV method (Cobas Bioanalyzer, 
Boehringer, Mannheim, Germany). Quantification of different lipopro- 
teins was carried out by precipitation. HDL cholesterol was determined 
by measuring cholesterol concentrations in the supernatant after pre- 
cipitation with HeparinMnCl,, HDL/LDL cholesterol was determined 
by measuring cholesterol concentration in supernatant after precipita- 
tion with 10% SDS in 0.15 M NaCl pH 9.0. LDL cholesterol levels were 
calculated from HDL/LDL minus HDL cholesterol evels. The free 
fatty acids in plasma were determined by an enzymatic calorimetric 
method (NEFA C kit, Wako Chemicals GmbH, Neuss, Germany). 
Thyroid hormones and TSH were measured by radioimmunoassay. 
Reagents used in the specific rat TSH-RIA were r-TSH-RP-2 (AFP- 
5153B) as reference preparation, anti r-TSH-S-5 (C 21381) as antibody 
and r-TSH-I-8 (AFP-8334B) as antigen for iodination (courtsey of the 
National Institute of Arthritis, Diabetes, Digestive and Kidney Dis- 
eases, Bethesda, MD, USA). RNA was isolated from liver by the gua- 
nidine isothiocyanate method [lo]. mRNA was isolated from RNA 
using the polyAT tract mRNA isolation system of Promega (Madison, 
WI, USA). 2 pg aliguots of poly A+ RNA were denatured and electro- 
phoresed in 1% agarose/formaldehyde v rtical gels. The separated 
RNAs were transferred to Nytran NY13 membrane (Schleicher and 
Schuel, Dassel, Germany) by pressure-blotting (Posiblot pressure blot- 
ter, Stratagene, La Jolla, CA, USA) and membranes were fixed using 
UV cross-linking (1 J/cm’). The RNA probes were labelled with digoxi- 
genin using a DIG RNA labelling kit (Boehringer Mannheim Biochem- 
ica, Mannheim, Germany). Labelled RNA probes were synthesized by 
in vitro transcription of DNA, cloned downstream of T7 or T3 promot- 
ers, with T7/T3 polymerases according to the manufacturers protocol. 
Dig-labelled probes were detected by an enzyme catalyzed chemilumi- 
nescence reaction which can be documented on X-ray film. The hybrid- 
ization and detection conditions were as described in the DIG-lumines- 
cence detection protocol (Boehringer Mannheim Biochemica, 
Mannheim, Germany). The X-ray films were scanned by densitometry 
using XRS/3CX scanner and Whole band analysis (version 2.4 1991) 
from Millinore Cornoration (Ann Arbor. MI, USA) to determine rela- 
tive RNA ievels. Ai internal standard blots were hybridized with a rat 
probe for C/EBP, a transcription factor that is not regulated at the 
mRNA level by several hormones and second messengers [ll]. All 
probes were hybridized at 68°C except he HMG-CoA reductase probe 
which was hybridized at 42°C. Routine quantification of relative 
mRNA levels was preformed by dotblot analysis on positively charged 
membrane (Boehringer Mannheim Biochemica, Mannheim, Germany) 
using probes labelled as above. 
2.4. Statistical analysis 
To evaluate differences between groups the Mann-Whitney test was 
used. 
3. Results 
3.1. Experiment I. Time-course of the effect of 
amiodarone 
Amiodarone treatment for 14 days resulted in a 0.35 
nM decrease of plasma T3 and a 0.9 mM increase of 
plasma cholesterol (Fig. 1). In control rats, treated with 
water by gastric tube for 14 days, plasma T, decreased 
slightly by 0.12 mM, but plasma cholesterol remained 
unchanged. Northern blots showed a decrease in the 
LDL receptor mRNA from day 8 onwards (insert of Fig. 
2). Further quantification of LDL receptor mRNA was 
preformed on polyA’ RNA by dotblot analysis. Ami- 
odarone caused a marked (about 50%) decrease in he- 
patic LDL receptor mRNA concentrations after 2 weeks 
(Fig. 2). No changes were observed in mRNA levels of 
HMG-CoA reductase, cholesterol 7a-hydroxylase and 
5’-deiodinase (data not shown). 
3.2. Experiment II. Amiodarone versus propylthiouracil 
treatment 
Daily food intake in the propylthiouracil-treated rats 
was not different from control rats who were pair-fed to 
the amiodarone-treated animals. A slight increase in 
body weight was observed in all groups. Propylthiouracil 
treatment decreased plasma T4 and T, concentrations 
and increased plasma TSH; it had no significant effect 
on plasma cholesterol. In contrast, amiodarone treat- 
ment resulted in a 60% increase of plasma cholesterol 
(HDL cholesterol as well as LDL cholesterol), despite a 
less pronounced rise of plasma TSH and a smaller de- 
crease of plasma T3 when compared to propylthiouracil 
treated animals (Fig. 3). No changes in plasma triglyc- 
erides and free fatty acids were observed. Northern blot 
analysis demonstrated a decrease of liver S-deiodinase 
mRNA in the propylthiouracil treated but not in the 
amiodarone treated animals (Fig. 4). Neither treatment 
resulted in a change in liver HMG-CoA reductase or 
cholesterol 7ol-hydroxylase mRNA levels. The hepatic 
LDL receptor mRNA levels were -50% lower in both 
amiodarone and propylthiouracil treated animals com- 
pared to controls. 
4. Discussion 
From the time-course studies we concluded that two 
weeks of amiodarone treatment sufficed for induction of 
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Fig. 1. Changes in plasma T3 and cholesterol values after amiodarone 
treatment. Rats were treated for 2, 4, 8 and 14 days with amiodarone. 
Bars represent difference between day 0 and day 2,4, 8 and 14, respec- 
tively (mean of two rats per time-point). 
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Fig. 2. Liver LDL receptor mRNA in rats treated with amiodarone. 
The figure shows the relative concentrations of mRNA for the LDL 
receptor, corrected for CYEBP Results are given as mean of a duplicate 
experiment for 2 rats per time-point. In the insert a typical Northern 
blot obtained with 2,ug poly A+ RNA from livers treated with amiodar- 
one is shown. 
the hypercholesterolemic effect. Consequently, amiodar- 
one was administered for 2 weeks in experiment II. Pro- 
pylthiouracil effectively induced hypothyroidism, as we 
could demonstrated by low T4 and T, and high TSH 
plasma concentrations and a decrease in liver S-deiodi- 
nase mRNA. Hypothyroidism is associated with hyper- 
cholesterolemia. In our experiments however, we found 
no significant increase in plasma cholesterol levels 
(P = 0.07). This may be due to the mild hypothyroid 
condition of the animals or the relatively short pro- 
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pylthiouracil treatment in our experiments. On the other 
hand, liver LDL receptor mRNA was decreased by 
~50% in the hypothyroid animals, which was also found 
in other studies [11,12]. It is possible that, in time, the 
decrease in LDL receptor mRNA/protein may lead to a 
further increase in plasma cholesterol evels. The level of 
hepatic HMG-CoA reductase and cholesterol 7a-hy- 
droxylase mRNA were not affected by propylthiouracil 
treatment. Day et al. [13] also found no decrease of the 
HMG-CoA reductase mRNA using methimazole for the 
induction of hypothyroidism. 
Amiodarone medication resulted in an increase of 
plasma T4 and a decrease in plasma T,, as described 
previously [3]. A new finding is that the level of liver 
5’-deiodinase mRNA during amiodarone medication is 
not altered. This is in line with kinetic studies showing 
inhibition of T4 transport into peripheral tissues by the 
drug [14]. The observed reduction in liver S-deiodination 
is caused by a reduced availability of the substrate T,, 
instead of a reduction of 5’-deiodinase protein [ 15,161. 
The amiodarone-induced hypercholesterolemia can- 
not be explained by the rise in TSH because the higher 
TSH levels in the mildly hypothyroid animals did not 
result in a substantial increase of plasma cholesterol. The 
~60% increase of plasma cholesterol during amiodarone 
medication was associated with a ~50% decrease of liver 
LDL-receptor mRNA, but not with changes in liver 
HMG-CoA reductase or cholesterol 7a-hydroxylase 
mRNAs. These findings suggest a diminished liver up- 
take of cholesterol via the LDL receptor as a major 
mechanism for the amiodarone-induced hyper- 
cholesterolemia. The exact mechanism in which ami- 
odarone causes a downregulation of the gene expression 
of the LDL receptor remains to be elucidated. Gene 
Fig. 3. Effect of amiodarone and propylthiouracil (PTU) treatment of rats for 14 days on thyroid function tests and plasma cholesterol 
(mean f S.E.M., n = 6). 
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Fig. 4. Dot-blot analysis of hepatic mRNA for C/EBP, LDL receptor, HMG-CoA reductase, cholesterol 7a-hydroxylase and 5’-deiodinase in control, 
amiodarone treated rats, and propylthiouracil treated rats. (A) The figure shows typical dot-blots obtained with 2 pg poly A’ RNA from livers for 
the LDL receptor (LDLr), HMG-CoA reductase (RED), cholesterol 7a-hydroxylase (7a-OH) and 5’-deiodinase (DEI)from the 3 experimental groups: 
amiodarone (AM), control (CON) and propylthiouracil (PTU). (B) The figure shows the relative contents (mean f S.E., n = 3) of liver mRNA 
corrected for the internal control C/EBP. 
expression of the LDL receptor is T,-dependent and pos- 
sible binding sites for the TX-receptor are present in the 
promotor region of the LDL receptor gene [17]. We have 
recently demonstrated that desethylamiodarone, the 
major metabolite of amiodarone, inhibits the binding of 
T, to the T,-receptor in a noncompetitive manner [18] 
and may therefore interfere with T, action. This could 
explain the modulation of the LDL receptor gene expres- 
sion by amiodarone, but not the absence of an effect of 
the drug on HMG-CoA reductase and cholesterol 701- 
hydrolyse gene expression. An effect of amiodarone on 
other transcription factors, on mRNA stability, or on the 
interaction between the T,-receptor and its responsive 
element cannot be excluded. 
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